Related Experiment Videos
Quality of life and the heart: evaluation of therapeutic alternatives
1Division of Geriatric Medicine, Royal Postgraduate Medical School, London.
Insights
Measuring quality of life in heart disease requires careful consideration of treatment effects versus patient experiences. Valid, repeatable methods are crucial for accurate assessment in clinical trials.
Area of Science:
- Cardiology
- Health Outcomes Research
- Clinical Trial Methodology
Background:
- Assessing quality of life (QoL) in cardiological disease is complex, influenced by disease severity, treatment outcomes, and study logistics.
- Selecting appropriate measurement tools is vital for valid, repeatable, and sensitive evaluation of treatment efficacy.
- Interpreting QoL data requires distinguishing treatment effects from trial participation benefits and aligning scores with patient daily life experiences.
Purpose of the Study:
- To discuss the criteria and methods for measuring quality of life in cardiological disease clinical trials.
- To highlight the importance of robust study design and data interpretation for accurate QoL assessment.
- To evaluate the impact of specific pharmacological treatments on patient quality of life.
Main Methods:
- Review of criteria for selecting quality of life measures in clinical trials.
- Discussion of instrumentation for valid and repeatable QoL assessments.
- Emphasis on the necessity of control data, often requiring double-blind, randomized trial protocols.
- Evaluation of long-term pharmacological treatments and their QoL implications.
Main Results:
- Continuous use of transdermal nitrates for angina can impair quality of life due to headaches and social limitations.
- Drug tolerance can limit the efficacy of treatments impacting quality of life.
- Health indices can be used to obtain QoL scores from patients who withdraw or die during trials.
Conclusions:
- Accurate quality of life measurement in cardiology necessitates rigorous methodology, including randomized controlled trials.
- The impact of pharmacological treatments on patient quality of life must be carefully evaluated.
- Consideration of both clinical outcomes and patient-reported experiences is essential for a comprehensive understanding of treatment effects.
Abstract:
The choice of criteria that should be used in cardiological disease in order to establish a meaningful measure of quality of life is influenced by the severity and nature of the disease, the expected benefits and adverse effects of treatment, and such considerations as the length of the study and availability of appropriate methods. Moreover, the selection of specific instrumentation should be made with a view to producing valid, repeatable results that allow sensitive assessment of the effects of treatment. The inclusion of a health index is one method of obtaining quality-of-life scores from patients who withdraw from a clinical trial or who die. Interpretation of quality-of-life results from clinical trials is not simple: for example, the effect of treatment must be distinguished from the benefit of trial inclusion; moreover, changes in quality-of-life scores should correspond to changes in the patients' own experiences of their daily lives. The measurement of quality of life, when the effect of treatment is being assessed, requires adequate control data. This usually necessitates a double-blind, randomised trial protocol. The quality of life of patients on long-term pharmacological treatment needs to be evaluated, and several groups of drugs commonly employed are discussed here. Transdermal nitrates for angina do impair quality of life if used continuously, by producing headaches and limiting social participation, while tolerance limits their efficacy.(ABSTRACT TRUNCATED AT 250 WORDS)